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Tracer-Based Metabolic NMR-Based Flux Analysis in
a Leukaemia Cell Line
John B. Carrigan+,[a] Michelle A. C. Reed+,[a] Christian Ludwig,[b] Farhat L. Khanim,[c]
Christopher M. Bunce+,[c] and Ulrich L. Gìnther+*[a]
Introduction
Our previous work[1–3] and that of others[4] showed that high
levels of reactive oxygen species (ROS) have a profound
impact on acute myeloid leukaemia (AML) cells, and that sus-
ceptibility to ROS represents an Achilles heel that can be used
to specifically target AML cells with novel therapies.
We have previously shown the anti-leukaemic and anti-lym-
phoma activity of a combination (denoted BaP) of two rede-
ployed drugs, the contraceptive steroid medroxyprogesterone
(MPA) and the lipid-regulating drug bezafibrate (BEZ).[1] Consis-
tently associated with BEZ treatment is the rapid and sustained
generation of ROS.[1] We have also shown that BaP treatment
has a profound effect on the metabolome of AML cell lines
(KG1a, K562, and HL60).[2] The most pronounced changes were
observed for metabolites of the Krebs cycle. HL60 cells showed
reduced levels of fumarate compared to succinate, which was
attributed to the formation of malonate under BaP treatment,
which inhibits succinate dehydrogenase.
Given these findings, and the success of these NMR studies
in elucidating mitochondrial insult by ROS, we used a tracer-
based metabolic analysis (metabolic flux analysis) to character-
ise the effect of this combination of drugs on central carbon
metabolism. Tracer-based metabolic analysis represents a form
of targeted metabolomics, in which the distribution of 13C
from an isotopically labelled metabolic precursor is traced
among various metabolites, allowing for a more quantitative
interpretation of metabolic changes than is currently afforded
by traditional 1D 1H spectra. Moreover, NMR spectroscopy
yields information on site-specific label incorporation. Tracer-
based studies enable specific assignments to metabolic path-
ways, depending on the choice of the isotopically labelled me-
tabolites. NMR spectroscopy and mass spectrometry have
been commonly used to determine the incorporation of iso-
topic precursors such as 13C-labelled forms of glucose and glu-
tamine (reviewed in Ref. [5]).
Here we report a tracer-based metabolic analysis of K562
cells with and without BaP treatment, in which we probe the
use of glucose and glutamine in central carbon metabolism.
We ascertained the early effects arising from BaP treatment by
monitoring label incorporation, as well as alterations to metab-
olites observed only in natural isotopic abundance. We used
[1-13C]glucose and [1,2-13C]glucose as tracers to probe label in-
corporation in glycolysis and transfer into the Krebs cycle, and
[3-13C]glutamine to further probe the Krebs cycle and glutami-
nolysis. Label incorporation into metabolites was examined
using 1H–13C heteronuclear single quantum coherence (HSQC)
NMR spectra. HSQC spectra show a signal per CH group, and
in addition, if acquired with sufficient resolution in the incre-
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mented 13C dimension, show couplings between adjacent car-
bons. The former data provide direct information about site-
specific label incorporation rates, the latter provides informa-
tion about label incorporation at adjacent carbon positions.[5]
Results
HSQC spectra of K562 cell extracts allowed unambiguous iden-
tification of approximately 40 metabolites, some of which
showed isotope enrichment for cells grown for 24 h with [1,2-
13C]glucose or [3-13C]glutamine. Cells were grown with labelled
precursors for 24 h, as this is the time frame in which label in-
corporation can be observed into a wide range of metabolites.
Reference spectra from cells grown with glucose and gluta-
mine of natural isotopic abundance were prepared as controls.
Although apoptosis or differentiation is usually not evident
until about 96 h, our previous work showed a distinct metabol-
ic response after 24 h. Therefore, we also chose a 24 h time
frame for the exposure to BEZ and MPA running in parallel
with label incorporation. For many of the observed metabolite
resonances, corresponding NMR signals could also be observed
in unlabelled samples grown with natural isotopic abundance
glucose or glutamine.
Here we examine metabolic pathways by using [1-
13C]glucose, [1,2-13C]glucose and [3-13C]glutamine to monitor
metabolism in K562 cells and determine how it is affected by
Bap treatment.
Glucose mainly feeds the pentose phosphate pathway and
glycolysis
Figure 1 shows the theoretical labelling patterns in glycolysis
and Krebs cycle intermediates arising from feedings cells with
[1,2-13C]glucose (Figure 1A) and [3-13C]glutamine (Figure 1B).
Figure 2 and Table S1 (in the Supporting Information) summa-
rise the experimentally observed incorporation of labels for
some key metabolites arising from [1,2-13C]glucose, observed
and quantified from K562 cells by HSQC spectra (see Table S1
for further details).
Labelling in ribose moieties
The highest isotopic enrichment levels observed were of the
ribose sugar resonances, due to pentose phosphate pathway
(PPP) activity. Interestingly, labelling of the ribose sugars is indi-
cative of a mix of both oxidative and non-oxidative PPP activi-
ty. In the oxidative PPP, the label from the C1 position of glu-
cose is lost when CO2 is released by the action of 6-phospho-
gluconate dehydrogenase, yielding ribose sugars labelled ex-
clusively at C1. This results in a single ribose signal for C1 in
the HSQC spectrum. In non-oxidative PPP, the 13C1¢13C2
moiety is retained and gives labelling of C1¢C2 and C4¢C5
moieties in the resulting ribose sugars. These two 13C frag-
ments produce doublets arising from scalar JCC couplings ob-
served at C2, C4 and C5.[6] From C1, three signals arise: the
middle singlet signal arises from the oxidative PPP with C2 un-
labelled and the outer doublet arises from the non-oxidative
PPP. As an example, Figure 3 shows the well-resolved adenine
ribose C1 signal from nicotine adenine dinucleotide (NAD+).
The signal arising from the natural abundance sample is very
weak (shown in black) relative to the signals measured in the
spectrum obtained from the [1,2-13C]glucose-fed cell extracts
(blue). Figure S1 shows all the 13C signals for uridine diphos-
Figure 1. A) Theoretical flow of 13C label from [1,2-13C]glucose, assuming
PDH-mediated flow of label into the TCA cycle (red balls indicate labelled
positions). B) Theoretical flow of 13C label from [3-13C]glutamine (blue balls
indicate labelled positions).
Figure 2. Percentage levels of label incorporation arising from both glucose
and glutamine labelling.
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phate (UDP). Here, the C1 regions suffer from substantial
signal overlap of the various uridine nucleotide species. How-
ever, doublets are clearly observed for C2 and C4, indicative of
non-oxidative PPP activity.
Labelling in glycolysis intermediates
Other large enrichments were observed for metabolites pro-
duced from pathways branching from glycolysis. For example,
glycerol 3-phosphate and glycerophosphocholine are labelled
predominantly at the C2 and C3 positions of the glycerol
moiety due to processing from [2,3-13C]glyceraldehyde 3-phos-
phate. Likewise, lactate and alanine are labelled at the C2 and
C3 positions due to the formation from [2,3-13C]pyruvate.
Labelling in Krebs cycle intermediates
Lower levels of label incorporation were observed for metabo-
lites arising from pyruvate entering the TCA cycle, predomi-
nately by pyruvate dehydrogenase (PDH)-catalysed condensa-
tion of [1,2-13C]acetyl-CoA with oxaloacetate. The glutamate la-
belling pattern is consistent with the incorporation by PDH
catalysis of 13C into a C4C5 fragment from [1,2-13C]glucose,
along with lower label incorporation at the C2 and C3 posi-
tions, possibly arising from pyruvate carboxylase activity or fur-
ther turns of the TCA cycle. The labelling patterns in both glu-
tathione and pyroglutamate in the g-glutamyl cycle, and in
proline are all consistent with flow of label from glutamate
(Figures 1A and 2).
Similarly, aspartate, produced from the TCA cycle intermedi-
ate oxaloacetate, is clearly labelled at the C2 and C3 positions.
Interestingly, this label is not transferred into asparagine. How-
ever, the label in aspartate is fed into pyrimidine-base ring syn-
thesis, as shown by the presence of multiplets in the spectra
arising from the aspartate-derived portion of pyrimidine rings
(Figure S2).
Four-carbon TCA cycle intermediates such as succinate, fu-
marate, malate and aspartate showed labelling of only approxi-
mately 5%, suggesting that glucose is not the primary source
of these TCA cycle intermediates. Following this observation,
additional experiments were conducted to probe the impor-
tance of glutamine as a possible nutrient source for the TCA
cycle. Other resonances arising from natural abundance metab-
olites were also observed in HSQC spectra but are not specifi-
cally labelled from glucose: glutamine is the main anaplerotic
substrate
Considering that few glucose-derived 13C carbon atoms en-
tered the Krebs cycle we wondered whether glutamine could
serve as an anaplerotic substrate in K562 cells. This was investi-
gated using [3-13C]glutamine as a tracer. Indeed, we observed
much higher label incorporation in Krebs cycle intermediates
compared to that observed if glucose was used as a tracer
(Figure 2, Table S1). The most intensely labelled carbon posi-
tions in metabolites (Table S1) corresponded to the expected
labelling pattern that would arise from the conversion of [3-
13C]glutamine to glutamate, catalysed by mitochondrial gluta-
minase, and subsequently to a-ketoglutarate (Figure 1B). The
overall label incorporation into the cellular pool of the four-
carbon Krebs cycle intermediates was typically fourfold higher
than that derived from [1,2-13C]glucose (Table S1).
Outside of the mitochondria, pyrimidine carboxyltransferase
catalyses the addition of aspartate to carbamoyl phosphate as
part of the first step in pyrimidine nucleotide synthesis. Per-
haps because of the much greater extent of labelling in aspar-
tate, label incorporation was observed in several intermediates
in this pathway; namely N-carbamoylaspartate, dihydroorotate,
orotate and orotidine, as well as in the pyrimidine rings of vari-
ous uridine and cytidine nucleotide species.
Curiously, no label incorporation was seen in lactate, alanine
or acetyl groups (by observing signals arising from the acetyl
groups of N-acetylated amino acids and acetic acid). This con-
trasts sharply with work by DeBerardinis et al. , who found that
60% of glutamine was converted to lactate and alanine in glio-
blastoma cells, a process that involves malate exiting the TCA
cycle and mitochondria with subsequent conversion to pyru-
vate by a malic enzyme, thereby generating sufficient NADPH
to support fatty acid biosynthesis.[7] Although it is currently not
understood what regulates this process, it is increasingly clear
that it is different between cancer cell types.
BaP treatment increases intracellular glutamine and reduces
de novo pyrimidine synthesis
As we have shown previously,[1] BaP treatment causes high
levels of ROS, as a consequence of the action of BEZ (see also
Figure S3). We observed a significant change in label incorpo-
ration with BaP treatment for a few metabolites only. The treat-
ment decreased label incorporation from [1,2-13C]glucose into
a-ketoglutarate and increased that for succinate. This is consis-
Figure 3. Overlay of the spectral region in which resonances corresponding
to the C1 position of NAD+ appear. Blue: control sample grown in [1,2-
13C]glucose-supplemented media; black: control sample grown in natural
isotopic abundance media.
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tent with ROS-mediated conversion of a-ketogluta-
rate to succinate, and with the previous results of Ti-
ziani and co-workers.[2] Equally, there was little
change in label incorporation observed in spectra
from [3-13C]glutamine-labelled cells upon BaP treat-
ment. Label incorporation into succinate increased
and labelling of a-ketoglutarate decreased, as ob-
served for labelled glucose. Moreover, aspartate and
acetyl-N-aspartate labelling increased slightly upon
BaP treatment, whereas the label incorporation in
pyrimidine synthesis intermediates N-carbamoylas-
partate, dihydroorotate and orotate was significantly
reduced. For the latter group, there were no signals
present in the reference natural abundance spectra.
Therefore, we reasoned that the reference signal had
intensity below the noise level in the spectrum. Con-
sequently, we were able to calculate minimum label incorpora-
tions by assuming that the reference intensity was the maxi-
mum noise in the reference spectrum.
Effects of BaP on pyrimidine synthesis
Figure 4 shows a region of the HSQC spectrum containing the
C3 cross peaks of N-acetylaspartate and N-carbamoylaspartate,
clearly illustrating their very different responses to BaP treat-
ment. Dihydroorotate and orotate signals, both downstream
metabolites in the pyrimidine synthesis pathway are also clear-
ly diminished. However, it remains enigmatic why pyrimidine
nucleotides show only a minimal, if any, reduction in label in-
corporation (see Table 1, [3-13C]glutamine section, C11, C12). To
resolve this puzzle we also measured the 1D spectra of unla-
belled samples (Figure S4). These showed a change in the bal-
ance between UDP-N-acetylglucosamine and other UDP-con-
taining species. Whereas just levels of UDP-glucose, UDP-glu-
curonate and UDP-galactose were clearly reduced with BaP
treatment, UDP-N-acetylglucosamine increased.
Effects of BaP on the g-glutamyl cycle
The levels of metabolites from the g-glutamyl cycle were also
perturbed by BaP treatment (Figure S5). 1H 1D spectra of unla-
belled samples showed that glutamate and particularly gluta-
mine both increased in levels on treatment with BaP (data not
shown). Analysis of peak intensities in HSQC spectra derived
from cell extracts grown in unlabelled media showed that BaP
treatment greatly increased the amounts of glutamine and py-
roglutamate, somewhat increased glutamate and slightly de-
creased glutathione levels (Table 1). Overall this might suggest
that cells respond to high concentrations of ROS by increasing
their glutamine uptake.
In spectra arising from [3-13C]glutamine-treated cells, label
incorporation at C3 can be assessed from the ratio of the sig-
nals of JCC-coupled doublet versus the singlet C4. This over-
comes the problem that C3 signals of glutamine and gluta-
thione are significantly overlapped. It is important to note that
the relative intensities of peaks in the glutathione multiplet
did not change significantly with BaP treatment (Table 2), dem-
onstrating no change in label incorporation.
Figure 4. Overlay to compare the effect of BaP treatment on resonances
from N-acetylaspartate (top left peak) and N-carbamoylaspartate (bottom
right peak). Red: control sample grown in [3-13C]glutamine; blue: BaP-treat-
ed sample.
Table 1. Natural abundance levels of g-glutamyl cycle metabolites from HSQC spec-
tra.
Myo C1/C3* Gln C4 Glu C4 GSH C4 Pyroglu C4
Control[a] 1.25Õ107 1.31Õ106 1.95Õ107 4.15Õ106 5.53Õ105
Bap 1.09Õ107 3.39Õ106 2.08Õ107 3.19Õ106 9.1Õ105
Control-scaled
intensity[b]
1.000 0.105 1.560 0.332 0.044
BaP-scaled
intensity[b]
1.000 0.311 1.908 0.293 0.083
BaP/control ratio 1.00 2.96 1.22 0.88 1.89
[a] Arbitrary intensity values from original data. [b] myo-Inositol C1 and C3 were used
as references, that is, it was assumed that their levels were not affected by BaP treat-
ment. Scaled intensity=metabolite intensity/myo-inositol intensity. Glu, glutamate;
Gln, glutamine; GSH, glutathione; Myo, myo-inositol ; Pyroglu, pyroglutamate.
Table 2. Labelling in the g-glutamyl cycle.
Metabolite Peak heights, control Õ106 Peak heights, BaP Õ106
Glutamate C4[a] doublet: 6.22+4.67 doublet: 8.00+5.94
singlet: 8.24 singlet: 12.9
ratio: 1.3 ratio: 1.1
Glutathione C4[a] doublet: 1.23+1.16 doublet: 1.01+0.92
singlet: 2.2 singlet: 2.26
ratio: 1.1 ratio: 0.9
Pyroglutamate C3[b] 4.55, 3.85 14.7, 15.9
[a] 13C4 signal intensities for doublet (arising from coupling to 13C3) and
singlet (with 12C3). [b] Directly observed C3 signal intensities for Ha and
Hb.
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Label incorporation into glutamate was also not significantly
affected by BaP treatment. By contrast, label incorporation
from [3-13C]glutamine into pyroglutamate increased threefold
upon BaP treatment (Table 2). The increase of pyroglutamate
labelling is consistent with cyclisation of glutamate or gluta-
mine to pyroglutamate mediated by ROS.
Discussion
Overall, the NMR analysis of label incorporation into metabo-
lites arising from labelled glucose and glutamine precursors
shows the significant potential of this approach for studying
metabolic mechanisms in human cell lines. Although this has
originally been recognised by Shulman and Ugurbyl and co-
workers[8–10] and later by Szyperski, Bailey, and Wìthrich,[11, 12]
the method of choice for most subsequent studies has been
mass spectrometry, probably owing to its much higher sensi-
tivity. However, the limitation of mass spectrometry is that it
provides less information from mass increments, whereas NMR
can in principle yield additional information for site-specific
label incorporation. If [1,2-13C]glucose is used, further informa-
tion arises from the 1JCC scalar coupling between adjacent car-
bons, especially as the C1 atom in glucose is abstracted in the
entry step to the oxidative PPP, but not for the non-oxidative
PPP branch. In some cases, this is also useful to determine
label incorporations into carbon atoms that cannot be easily
resolved owing to overlap if an adjacent CH can be observed
as a reporter. This has been shown for glutamine-related me-
tabolites.
HSQC spectra show a larger number of metabolites than di-
rectly observed 1D 13C spectra, owing to its much higher sensi-
tivity. This is of course limited to carbon atoms with an at-
tached proton, although label incorporation into CO and COO
groups can often be inferred from the signals of neighbouring
CHs. In order to resolve JCC couplings, at least 4096 increments
need to be acquired, resulting in an overall acquisition time of
more than 4 h for two increments with a recycle time of 2 s.
K562 central carbon metabolism
This analysis provides new insights into the metabolism of
K562 leukaemic cells. This cell line was derived from a BCR–
ABL translocation-positive blast-crisis chronic myeloid leukae-
mia and is an established cell-line model for leukaemia. Our
data demonstrates that large amounts of glucose are funnelled
into the PPP, as observed by 13C labelling of ribose. The ob-
served labelling pattern is indicative of a mix of oxidative and
non-oxidative PPPs, as evidenced by C1–C2 and C4–C5 cou-
plings. This was further supported by label incorporation into
various ribose sugars arising from [1-13C]glucose, which is only
possible by the non-oxidative pathway, for example, 36% label
incorporation into C1 of adenosine diphosphate.
Further label incorporation was observed in other glycolysis-
related metabolites such as glycerol 3-phosphate and lactate,
although levels were lower than those observed for ribose
sugars. In the Krebs cycle, label incorporations in glutamate,
succinate, fumarate and malate were all low (5%) from glu-
cose and larger (13–50%) from glutamine. This is in accord-
ance with a strong Warburg effect, by which lactate is pro-
duced and entry of pyruvate into the Krebs cycle is blocked.
Large amounts of glucose-derived label diverted into the PPP
have previously been observed for cancer cells.[13] The high
levels of label incorporation from glutamine indicate highly
active glutaminolysis.
In K562 cells, glutamine-derived label was not observed in
lactate or alanine. This is in sharp contrast to the work of De-
Berardinis et al. ,[6] who found that 60% of glutamine converted
to lactate in glioblastoma cells. Neither did we observe label
incorporation into asparagine, although aspartate is labelled
from glucose and, to a lesser degree, from glutamine.
Effects of BaP treatment
Tracer-based metabolic analysis of BaP-treated K562 cells con-
firmed that a-ketoglutarate levels are reduced, whereas succi-
nate was increased after a 24 h treatment with BaP. Important-
ly, BaP treatment reduced label incorporation into pyrimidine
synthesis intermediates, especially those of N-carbamoylaspar-
tate, orotic acid and dihydroorotic acid. The de novo synthesis
of pyrimidines is crucially important for the cell and its pertur-
bation is likely to have huge implications outside of the imme-
diate synthesis pathway as highlighted in a recent study by He
et al. in 2014.[14] After assembly from bicarbonate, glutamine
and adenosine triphosphate, uridine and cytidine nucleotides
are fuels for the synthesis of RNA, DNA, phospholipids, UDP
sugars and glycogen. In this study, we have for the first time
tracked all stages of this process through the labelling of as-
partate from our [3-13C]glutamine source. It remains puzzling
why label incorporation into the pyrimidine end product is
always high and not significantly affected by BaP treatment.
One possible explanation is that the pyrimidine pool builds up
prior to the inhibition of pyrimidine synthesis or that the pyri-
midine salvage pathway becomes more active to maintain
these pools.
BaP treatment causes an unexpected shift in the balance of
different UDP species, showing decreases in the amounts of
UDP-glucose, UDP-glucuronate and UDP-galactose and an in-
crease for UDP-N-acetylglucosamine. This is apparent from the
ribose signals of UDP compounds in 1D spectra of unlabelled
samples, whereas the pyrimidine signals of individual UDP spe-
cies are not separately resolved.
Conclusion
The data presented in this study highlights the potential of iso-
topic tracer-based profiling in understanding cancer cell me-
tabolism and any subsequent metabolic changes arising from
treatment. K562 cells clearly display high glycolytic activity, al-
though this is not linked to the Krebs cycle, but rather towards
the production of ribose sugars in the PPP and lactate. More-
over, we have observed glutamine as an anaplerotic source for
the Krebs cycle. Our analysis also shows the effects of BaP
treatment, specifically changes in succinate and a-ketogluta-
rate levels, and a reduction of pyrimidine synthesis intermedi-
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ates. Metabolic changes observed in AML cell lines in response
to BaP treatment reflect the downstream effect of ROS as pre-
viously reported.
Experimental Section
Metabolic labelling and NMR sample preparation
K562 cells were maintained in an exponential phase (2.5–10Õ
105 cellsmL¢1) in RPMI-1640 medium supplemented with heat-inac-
tivated 10% FBS and penicillin/streptomycin (Gibco, Life Technolo-
gies Ltd, Paisley, UK) at 37 8C and 5% CO2 in a humidified incuba-
tor. A sufficient number of cells, 5Õ107 exponentially growing
K562 cells per control or treatment, were harvested by centrifuga-
tion (800 g, 5 min).
For tracer-based metabolic analysis, standard media with natural
isotopic abundance precursors or 100% labelled media were used.
Media containing 100% 13C-labelled precursor was prepared by
adding [1,2-13C]glucose (2 gL¢1, Isotec; Sigma–Aldrich) to glucose-
free RPMI-1640 (Gibco) or [3-13C]glutamine (300 mgL¢1, Isotec;
Sigma–Aldrich) to glutamine-free RPMI-1640 (Gibco). BEZ (0.5 mm)
and MPA (5 mm ; Sigma–Aldrich), or the equivalent concentrations
of DMSO and ethanol solvent controls, were added to media. Cell
pellets were resuspended in the relevant media and incubated for
24 hrs with labelled precursors and/or BaP at 37 8C and 5% CO2 in
a humidified incubator.
Cells were harvested by centrifugation (800 g, 10 min) and the pel-
lets were washed with PBS and transferred to 1.8 mL glass vials in
PBS (1 mL). Cells were centrifuged (4000 g, 4 8C, 1 min), then the
PBS was removed and the cell pellet resuspended in methanol
(400 mL) that had been pre-chilled over dry ice, thus freezing the
samples. Samples were kept on dry ice and then stored at ¢80 8C.
After removal from ¢80 8C storage, the vials were placed on wet
ice and distilled H2O (325 mL) and chloroform (400 mL, prechilled on
wet ice) were added before vortexing for 30 s followed by incuba-
tion on ice for 10 min to allow the phases to separate. Following
centrifugation (1500 g, 4 8C, 10 min), the polar (upper) fraction was
transferred to Eppendorf tubes and dried overnight in a centrifugal
vacuum concentrator.
NMR data acquisition
Polar extracts were resuspended in metabolomics buffer (60 mL;
sodium phosphate buffer, 0.5 mm trimethylpropanoic acid, 10%
D2O, pH 7) with vortexing, and supernatant (40 mL) was transferred
to champagne vials. Supernatant (35 mL) was then transferred to
1.7 mm NMR tubes and kept at 4 8C prior to measurement.
All spectra were acquired at 298 K on a Bruker 600 MHz spectrom-
eter with a TCI 1.7 mm z-PFG cryogenic probe using a cooled
Bruker SampleJet autosampler. In all experiments, the 1H carrier
was set to the water frequency and the 1H 908 pulse was calibrated
at a power of 0.326 W.
For the 1H 1D spectra, the standard Bruker pulse sequence noe-
sygppr1d for 1D NOESY with water presaturation was used. The
key parameters were as follows: spectral width: 12.15 ppm
(7288.6 Hz); complex points, TD: 32768; interscan delay, d1: 4 s;
short NOE mixing time, d8: 10 ms; number of scans, ns=256;
dummy scans, ds=8. The total experiment time was 28 min.
For the 1H–13C HSQC spectra the pulse sequence used was based
on the Bruker standard pulse program hsqcetgpsp, which uses
echo/anti-echo time-proportional phase incrementation gradient
selection, with additional gradient pulses to improve water sup-
pression. Key parameters for the 1H observation dimension were:
a spectral width of 7812.5 Hz, 2048 complex points in the direct di-
mension, 4096 increments for the 13C indirect dimension with
a spectral width of 159.0 ppm. Spectra were acquired with two
scans and an interscan delay of 1.5 s, giving a total experiment
time of approximately 4 h. All spectra were processed using
NMRLab[15] in MATLAB. Cosine-squared window functions were ap-
plied to both dimensions.
Analysis of 2D spectra
Peaks were picked in a semi-automated manner using Metabo-
Lab.[16] To calculate percentage label incorporations, the cross
peaks in labelled spectra (spectra from cell extracts grown in la-
belled media) and reference spectra (spectra from cell extracts
grown in natural isotopic abundance media) were compared. The
13C isotope constitutes about 1% of naturally occurring carbon.
Therefore, for more concentrated metabolites, cross peaks could
be observed in the reference spectra. Peak intensities in control
and reference spectra were used to calculate the percentage incor-
poration of 13C labels into particular carbon atoms of a given me-
tabolite following the equation %incorporation=100N/(DS) where
N is the intensity of the selected peak of the metabolite in labelled
media, D is the intensity of the selected peak of the metabolite in
the control spectrum, and S is the mean of a scale factor. The scale
factor=Nr/Dr, where Nr is intensity of peak i from a reference me-
tabolite in the numerator spectrum and Dr is the intensity of peak i
from a reference metabolite in the denominator spectrum. The ref-
erence metabolite was chosen because it was one of a group of
metabolites that did not change in intensity significantly between
treated and untreated spectra or between spectra for enriched and
natural abundance media. Results were similar using valine, leucine
or isoleucine as the reference metabolite. Labelling was not consid-
ered significantly changed unless BaP treatment changed percent-
age label incorporation by at least a factor of 2.
In some spectra, peaks were not observed owing to their low in-
tensity. In such cases, the peak intensity was set to the estimated
noise level in that spectrum. That noise level is evaluated by
searching for the maximum of the absolute value of the intensity
seen in a region devoid of real signals. When calculating percent-
age incorporations of 13C, it is the 12C reference spectrum peak in-
tensity that might be missing. Substituting the dummy peak inten-
sity will cause a tendency of the percentage incorporation of 13C to
be (conservatively) underestimated“.
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